Children have a mild course of acute COVID-19 in most of the cases. However, a few non-controlled studies on children present an evaluation of long-term recovery from SARS-CoV-2 infection. Mostly, the studies were conducted on a small sample size with children aged between 0-17 years.
The study aimed to evaluate symptoms and duration of 'long COVID' in children.
Data collection was done through a nationwide cohort study with 37,522 RT-PCR verified SARS-CoV-2 infected children, aged between 0-17 years (response rate 44.9%). Further, the study also had a group of 78,037 children as control (response rate 21.3%). An electronic questionnaire was used to collect data.
It was obtained that symptoms lasting > 4 weeks were common among both SARS-CoV-2 children and controls. However, SARS-CoV-2 infected children with the age of 6-17 years reported symptoms more frequently than the control group (percent difference 0.8%).
The most reported symptoms among pre-school children were
Fatigue Risk Difference (RD) 0.05 (CI 0.04-0.06)
Loss of smell RD 0.01 (CI 0.01-0.01)
Loss of taste RD 0.01 (CI 0.01-0.02)
Muscle weakness RD 0.01 (CI 0.00-0.01)
However, in school children, respiratory problems RD 0.03 (CI 0.03-0.04), dizziness RD 0.02 (CI 0.02-0.03), chest pain RD 0.01 (CI 0.01-0.01) were also observed along with the above-mentioned symptoms.
Furthermore, children in the control group experienced significantly more concentration difficulties, headache, muscle and joint pain, cough, nausea, diarrhea and fever than SARS-CoV-2 infected.
In most of the cases, 'long COVID' symptoms resolve in children within 1-5 months. Therefore, it can be interpreted that long COVID in children is rare and mainly of short duration.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer
2.
EVP Beats Cisplatin for Resectable MIBC
3.
For elderly, unfit patients, the all-oral AML regimen shows promise.
4.
Study sets benchmark for treatment of advanced cervical cancer
5.
For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.
1.
Case-Based Learning on Adaptive Management of Oligometastatic Disease Across Treatment Phases
2.
The Link Between Being Overweight and Cancer
3.
Uncovering the Mysteries of the RDW Blood Test
4.
Vaso Occlusive Crisis: Understanding the Painful Reality of Sickle Cell Disease
5.
Optimizing the Diagnosis and Treatment of Hematological Diseases Through Artificial Intelligence
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Common Cancer Myths Debunked
2.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
5.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation